.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB14_Valganciclovir.Valganciclovir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB14_Valganciclovir.Valganciclovir| name: | Valganciclovir |
| ATC code: | J05AB14 | route: | oral |
| n-compartments | 1 |
Valganciclovir is an oral prodrug of ganciclovir, an antiviral agent used to treat cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as organ transplant recipients and those with HIV/AIDS. It is currently approved and widely used for CMV prophylaxis and treatment.
Pharmacokinetic parameters reported in healthy adult volunteers (median age 26 years), following a single oral dose of valganciclovir, under fasting conditions.
Nguyen, T, et al., & Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02254-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318012
Perrottet, N, et al., & Buclin, T (2009). Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrobial agents and chemotherapy 53(7) 3017–3023. DOI:10.1128/AAC.00836-08 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19307355
Vezina, HE, et al., & Balfour, HH (2014). Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. British journal of clinical pharmacology 78(2) 343–352. DOI:10.1111/bcp.12343 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24528138